Literature DB >> 9973161

Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients.

G F Wiesinger1, M Quittan, M Graninger, A Seeber, G Ebenbichler, B Sturm, K Kerschan, J Smolen, W Graninger.   

Abstract

OBJECTIVE: The benefit of long-term physical training in patients with chronic polymyositis or dermatomyositis (PM/DM) was studied prospectively.
METHODS: Eight patients with chronic PM/DM participated in a training programme for 6 months. A group of five PM/DM patients without any physical training was observed for control purposes.
RESULTS: While there was no significant change in serum creatine phosphokinase (CPK) levels, the 'activities of daily living (ADL)' score improved significantly (P < 0.03), peak isometric torque (PIT) generated by muscle groups in the lower extremities rose significantly (P < 0.03) and there was a statistically highly significant increase in peak oxygen uptake (VO2max) relative to body weight (P < 0.02) due to the long-term training. The patients improved their aerobic capacity by 28%, which is clinically significant. In the untrained patients, no improvement in these target parameters was observed.
CONCLUSION: In clinically stable DM/PM patients, long-term physical training can safely be performed and is recommended as part of a comprehensive rehabilitation management, particularly in view of the cardiopulmonary risk in these patients.

Entities:  

Mesh:

Year:  1998        PMID: 9973161     DOI: 10.1093/rheumatology/37.12.1338

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  16 in total

Review 1.  Clinical trials review: idiopathic inflammatory myopathy.

Authors:  C V Oddis
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  The relevance of applying exercise training principles when designing therapeutic interventions for patients with inflammatory myopathies: a systematic review.

Authors:  Pierrette Baschung Pfister; Eling D de Bruin; Bernadette C Tobler-Ammann; Britta Maurer; Ruud H Knols
Journal:  Rheumatol Int       Date:  2015-08-14       Impact factor: 2.631

3.  [Sports and exercise therapy in inflammatory rheumatic diseases].

Authors:  Wolfgang Hartung; Philipp Sewerin; Benedikt Ostendorf
Journal:  Z Rheumatol       Date:  2021-03-08       Impact factor: 1.372

Review 4.  Exercise: an important component of treatment in the idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 5.  Strength training and aerobic exercise training for muscle disease.

Authors:  Nicoline Bm Voet; Elly L van der Kooi; Baziel Gm van Engelen; Alexander Ch Geurts
Journal:  Cochrane Database Syst Rev       Date:  2019-12-06

Review 6.  Exercise in inflammatory myopathies, including inclusion body myositis.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

Review 7.  Physical activity in idiopathic inflammatory myopathies: two intervention proposals based on literature review.

Authors:  Rossella Talotta; Irene Porrello; Roberto Restuccia; Ludovico Magaudda
Journal:  Clin Rheumatol       Date:  2021-10-19       Impact factor: 2.980

8.  Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle.

Authors:  Stina Salomonsson; Cecilia Grundtman; Shi-Jin Zhang; Johanna T Lanner; Charles Li; Abram Katz; Lucy R Wedderburn; Kanneboyina Nagaraju; Ingrid E Lundberg; Håkan Westerblad
Journal:  Muscle Nerve       Date:  2009-05       Impact factor: 3.217

Review 9.  Inflammatory muscle disease: clinical presentation and assessment of patients.

Authors:  Helene Alexanderson; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

10.  Responsiveness to exercise training in juvenile dermatomyositis: a twin case study.

Authors:  Clarissa Omori; Danilo M L Prado; Bruno Gualano; Adriana M E Sallum; Ana L Sá-Pinto; Hamilton Roschel; Maria B Perondi; Clovis A A Silva
Journal:  BMC Musculoskelet Disord       Date:  2010-11-25       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.